New evidence of the dramatic effectiveness of bremelanotide (PT-141) at increasing sexual receptivity in women was presented on February 25, 2007, at the annual meeting of the International Society for the Study of Women's Sexual Health. A Phase II clinical trial showed that women taking the drug felt a "tingling warm" sensation, felt "intense arousal" that lasted 6 to 72 hours, initiated sex with their partners and then "were completely focused on sex during the act."

Twenty-seven women took part in the clinical test, some taking bremelanotide and some a placebo (sugar pill). They completed questionnaires before and after taking the medicines. Those taking the PT141 showed far more sexual effects than those taking the placebo..